About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

215.43 +4.70 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% ga... 
Via StockStory
Topics Stocks
News headline image
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.6% in the afternoon session after the company received an analyst upgrade from Wells F... 
Via StockStory
Topics World Trade
Top S&P500 movers in Monday's session ↗
Via Chartmill
Gapping S&P500 stocks in Tuesday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
From Biogen Inc.
Via GlobeNewswire
News headline image
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? ↗
Or is the biotech's best days in the rearview mirror? 
Via The Motley Fool
News headline image
1 S&P 500 Stock for Long-Term Investors and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
News headline image
Why Biogen Stock Got Mashed on Monday ↗
Its first-quarter expenses will be notably higher than anticipated. 
Via The Motley Fool
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis... 
Via MarketMinute
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive... 
Via MarketMinute
News headline image
Why Biogen Stock Sank While the Market Soared on Thursday ↗
It's reaching into its coffers for a $5.6 billion acquisition. 
Via The Motley Fool
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
Top S&P500 movers in Tuesday's session ↗
Via Chartmill
News headline image
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
Via AB Newswire
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY).... 
Via Finterra
Topics Economy Intellectual Property
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.